EXHIBIT 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Mirati Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

Dated: October 30, 2020

BOXER CAPITAL, LLC
By:	/s/ Aaron I. Davis
Name:	Aaron I. Davis
Title:	Chief Executive Officer
BOXER ASSET MANAGEMENT INC.
By:	/s/ Jason Callender
Name:	Jason Callender
Title:	Director
BRASLYN LTD.
By:	/s/ Jason Callender
Name:	Jason Callender
Title:	Director
MVA INVESTORS, LLC
By:	/s/ Aaron I. Davis
Name:	Aaron I. Davis
Title:	Authorized Signatory
LOCKEND FIVE, LLC
By:	/s/ Greg Miller
Name:	Greg Miller
Title:	Manager
JOSEPH C. LEWIS
By:	/s/ Joseph C. Lewis
	Joseph C. Lewis, Individually
IVAN M. LIEBERBURG
By:	/s/ Christopher Fuglesang
	Christopher Fuglesang, Attorney-in-Fact*

AARON I. DAVIS
By:	/s/ Aaron I. Davis
	Aaron I. Davis, Individually
SHEHAN B. DISSANAYAKE
By:	/s/ Shehan B. Dissanayake
	Shehan B. Dissanayake, Individually
CHRISTOPHER FUGLESANG
By:	/s/ Christopher Fuglesang
	Christopher Fuglesang, Individually